Install Free Gold Price Widget!
Install Free Gold Price Widget!
Install Free Gold Price Widget!
|
- Home - Siegfried
Siegfried is a leading contract development and manufacturing organization with a global network of 13 production sites on three continents With 150 years of pharmaceutical and chemical experience, we are taking your innovations to industrial scale
- Company - Siegfried
As a fully integrated CDMO, Siegfried is one of the few organizations today that can carry out the development and manufacturing of APIs and finished dosage forms under one roof This unique combination of know-how and experience makes us the most trusted partner in the pharmaceutical industry
- Changes in Siegfried’s Management Team
Wolfgang Wienand is stepping down as Chief Executive Officer of Siegfried and will join Lonza in summer 2024 The Board of Directors of Siegfried has appointed CFO Reto Suter as CEO ad interim He will assume this additional responsibility as of May 1 st, 20 24 The search for the new Siegfried CEO has been initiated
- Locations - Siegfried
Siegfried Hameln is one of Siegfried’s six Drug Products sites globally It is a leading manufacturer of parenteral solutions, producing a wide range of aseptic and terminally sterilized products in ampoules and vials, with a dedicated development center for sterile injectables
- Leadership - Siegfried
Elodie Carr-Cingari (1974) was elected to the Board of Siegfried Holding AG in 2023 and chairs Siegfried’s Audit Committee She has been the Chief Financial Officer of the Landis+Gyr Group since 2020
- Marcel Imwinkelried appointed as new CEO - Siegfried
The Board of Directors of Siegfried Holding AG has appointed Marcel Imwinkelried as the new CEO with effect as of September 1, 2024 He will succeed Reto Suter, who has been leading the Siegfried Group as CEO ad interim since May 1, 2024, and will now focus again on his role as CFO
- Siegfried acquires majority stake in DINAMIQS to establish a best-in . . .
Siegfried announces the acquisition of a 95% stake in DINAMIQS, a Swiss-based biotechnology company focused on the development and manufacturing of viral vectors for cell and gene therapies; Siegfried will bring DINAMIQS’ capabilities to commercial scale and establish DINAMIQS as a best-in-class biotech CDMO for cell and gene therapies
- Investors - Siegfried
Siegfried supplies approximately 200 out of 1500 APIs approved by the FDA We serve more than 500 customers globally, and up to one billion people come in contact with Siegfried products every year Over 100 million doses of Covid-19 vaccines have been manufactured by Siegfried Learn more
|
|
|